The company has reported a net income was $6.48m, or $0.02 per diluted share, compared to a net loss of $3.15m, or $0.02 loss per diluted share, for the same period in 2010.
For the first quarter of 2011, the company’s operating income was $75.13m, compared to $16.37m for the same period in 2010.
Valeant Pharma chairman and CEO Michael Pearson said their performance in the first quarter is a strong start to what they believe will be another successful year for the company.
"Our specialty businesses performed well and our branded generic operations, in particular Central Europe, exceeded our expectations this quarter," Pearson said.